EnGen Bio
- Company typePrivate
- Founded2016
- HeadquartersRedwood City, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
EnGen Bio firmographics
Firmographics- Name
- EnGen Bio
- Website
- https://engenbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
EnGen Bio industry classification
Industry- Product category
- Influenza Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
- akta.pro secondary industry
- Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)
Keywords
Where EnGen Bio is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Markets served
EnGen Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
EnGen Bio product offering
Product offeringCore offering
EnGen Bio is a development-stage biotechnology company pioneering a new approach to preventing and treating influenza. The company is advancing novel influenza therapeutics and preventive technologies, with operations based in Redwood City, California, and a small team of 1-10 employees.
Product overview
enGen offers a unified CAPS (Core Administrative Processing System) platform as its primary product offering. The platform provides end-to-end automation solutions for healthcare administrative functions including enrollment, claims processing, and customer service. The CAPS system integrates an AI Claims Examiner component that leverages process automation and anomaly detection to resolve suspended claims. The company, a wholly owned healthtech subsidiary of Highmark Health, positions its CAPS platform as a comprehensive solution for healthcare payers seeking to streamline administrative operations.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Resolved 2.19 million suspended claims through AI Claims Examiner
- +1 more outcomes
Companies that use EnGen Bio
Customer profileIdeal customer profiles2 records
EnGen Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature1 record
EnGen Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Highmark HealthcoreenGen is a wholly owned healthtech subsidiary of Highmark Health. This is a parent-subsidiary relationship where enGen operates as an independent subsidiary within the Highmark Health corporate structure. The CAPS platform serves the healthcare administrative needs of the broader Highmark Health organization and potentially external healthcare clients.
Recent moves3 records
EnGen Bio competitors and assessment
Company assessmentDirect peers
- Codagenix: Clinical-stage synthetic biology company developing live-attenuated vaccines for influenza and other infectious diseases using a rationally designed codon-deoptimization platform — a comparable early-stage influenza vaccine developer.
- FluGen: Clinical-stage biotech developing intranasal, replication-competent influenza vaccines with improved efficacy versus standard-of-care injectables — directly comparable novel-approach influenza vaccine developer.
- Vaxart: Clinical-stage company developing oral recombinant vaccines including an oral influenza candidate — comparable novel-delivery influenza vaccine platform at similar stage of development.
Broad incumbents
- Novavax: Established recombinant nanoparticle vaccine platform developer with COVID-19 and seasonal influenza programs — relevant incumbent comparator for novel protein-based or recombinant influenza approaches.
- Moderna: Major mRNA vaccine developer with an FDA-approved seasonal influenza vaccine (mRNA-1010) — the leading novel-modality incumbent in the very market EnGen Bio targets.
- CSL Seqirus: Global influenza vaccine leader (Fluad, cell-based and adjuvanted platforms) — establishes the dominant commercial and manufacturing standard in seasonal and pandemic influenza.
- GSK: Major influenza vaccine manufacturer (Fluarix, Flulaval) and a likely strategic acquirer; relevant comparator for regulatory pathway and commercial scaling benchmarks.
- Sanofi: Largest global influenza vaccine manufacturer (Fluzone, Flublok) and a likely strategic acquirer or competitor for any novel influenza platform; sets the bar for clinical and commercial execution.
Emerging players
- CureVac: mRNA-based vaccine developer with infectious disease programs including influenza candidates — comparable novel-modality vaccine peer, more advanced and publicly listed.
- Arcturus Therapeutics: mRNA-based therapeutics and vaccines company with an infectious disease pipeline including influenza-relevant programs — comparable novel modality vaccine developer, more advanced.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
EnGen Bio social profiles
Digital presenceEnGen Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
EnGen Bio leadership team
Management profileNumber of profiles
Profiles1 record
EnGen Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EnGen Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EnGen Bio
What does EnGen Bio do?
EnGen Bio is a development-stage biotechnology company pioneering a new approach to preventing and treating influenza. The company is advancing novel influenza therapeutics and preventive technologies, with operations based in Redwood City, California, and a small team of 1-10 employees.
Is EnGen Bio a public or private company?
EnGen Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EnGen Bio founded?
EnGen Bio was founded in 2016. It employs 1 to 10 people.
Where is EnGen Bio based?
EnGen Bio is headquartered in Redwood City, United States, in the North America region.
Who are EnGen Bio's main competitors?
Direct peers on record are Codagenix, FluGen and Vaxart. Broad incumbents are Novavax, Moderna, CSL Seqirus, GSK and Sanofi. Emerging players are CureVac and Arcturus Therapeutics.
Does EnGen Bio have an API?
No public API is recorded for EnGen Bio.
What industry is EnGen Bio in?
EnGen Bio's product category is Influenza Therapeutics. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 541714.